Effects of acid proteinase inhibitors on human neutrophil chemotaxis and lysosomal enzyme release. II. Bromphenacyl bromide and 1,2-epoxy-3-(p-nitrophenoxy)propane.
Two active site inhibitors of acid proteinases were tested for their effects on human neutrophil chemotaxis and lysosomal enzyme release. Both bromphenacyl bromide (BPAB) and epoxy-p-nitrophenoxypropane (EPNP) inhibited chemotaxis and chemotaxin-induced enzyme release elicited by pepstatin and formylmethionyl peptides, which share membrane receptors, and also by zymosan-activated serum, the major active component of which (C5a) occupies a different receptor. In contrast to the previously tested acid protease inhibitor diazoacetylnorleucine methyl ester, neither BPAB nor EPNP blocked binding of [3H]fMLP to neutrophils. Thus BPAB and EPNP inhibit chemotaxin-mediated neutrophil functions, but not by interaction with the chemotaxin receptor.
D000098:Acetophenones / Q000494:pharmacology*; D000135:Acid Phosphatase / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004151:Dipeptides / Q000494:pharmacology; D004852:Epoxy Compounds / Q000494:pharmacology; D006801:Humans; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology*; D009113:Muramidase / Q000378:metabolism; D009239:N-Formylmethionine / Q000031:analogs & derivatives / Q000494:pharmacology; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009504:Neutrophils / Q000187:drug effects; D009596:Nitrophenols / Q000494:pharmacology*; D009842:Oligopeptides / Q000494:pharmacology; D010436:Pepstatins / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*
D000098:Acetophenones; D004151:Dipeptides; D004852:Epoxy Compounds; D009596:Nitrophenols; D009842:Oligopeptides; D010436:Pepstatins; D011480:Protease Inhibitors; C017330:N-formylmethionylphenylalanine; D009239:N-Formylmethionine; D009240:N-Formylmethionine Leucyl-Phenylalanine; C007606:1,2-epoxy-3-(p-nitrophenoxy)propane; D000135:Acid Phosphatase; D009113:Muramidase; C006821:4-bromophenacyl bromide